Rezultaty - Catherine E. Chaillan Huntington

  • Rezultaty 1 - 2 Rezultaty od 2
Redukuj rezultaty
  1. 1
    Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

    Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction od Elizabeth England, D. Gareth Rees, Ian C. Scott, Sara Carmen, Denice T. Y. Chan, Catherine E. Chaillan Huntington, Kirsty F. Houslay, Teodor Erngren, Mark Penney, Jayesh B. Majithiya, Laura Rapley, Dorothy A. Sims, Claire Hollins, Elizabeth C. Hinchy, Martin Strain, Benjamin Kemp, Dominic J. Corkill, Richard May, Katherine A. Vousden, Robin Butler, Tomas Mustelin, Tristan J. Vaughan, David C. Lowe, Caroline Colley, E. Suzanne Cohen

    Wydane 2023
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:
  2. 2
    Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation

    Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation od E. Suzanne Cohen, Ian C. Scott, Jayesh B. Majithiya, Laura Rapley, Benjamin Kemp, Elizabeth England, D. Gareth Rees, Catherine L. Overed‐Sayer, Joanne Woods, Nicholas J. Bond, Christel Séguy Veyssier, Kevin J. Embrey, Dorothy A. Sims, Michael Snaith, Katherine A. Vousden, Martin Strain, Denice T. Y. Chan, Sara Carmen, Catherine E. Chaillan Huntington, Liz Flavell, Jianqing Xu, Bojana Popovic, Christopher E. Brightling, Tristan J. Vaughan, Robin Butler, David C. Lowe, Daniel R. Higazi, Dominic J. Corkill, Richard May, Matthew A. Sleeman, Tomas Mustelin

    Wydane 2015
    Dokumenty pełnotekstowe Dokumenty pełnotekstowe
    Artigo
    Dodaj do listy ulubionych książek
    Zapisane w:

Narzędzie wyszukiwania: